Literature DB >> 10824881

Evaluation of gut motility in type II diabetes by the radiopaque marker method.

M Iida1, M Ikeda, M Kishimoto, T Tsujino, H Kaneto, M Matsuhisa, Y Kajimoto, T Watarai, Y Yamasaki, M Hori.   

Abstract

BACKGROUND: The clinical usefulness of the radiopaque marker method for detecting diabetic gastrointestinal motility disturbances, was evaluated by examining 21 type II diabetes subjects who did not have any neuropathic symptoms.
METHODS: After administration of a Sitzmark capsule, markers were located using plain abdominal radiographs, and the transit time of the markers through seven areas of digestive tract was calculated by Arhan's methods. The plasma concentration of acetaminophen at 45 min after oral administration was measured to evaluate gastric emptying time. The coefficient of variation of R-R intervals on the electrocardiograms (CV(R-R)) was measured to evaluate parasympathetic autonomic function.
RESULTS: In the diabetics, the average (+/- SD) transit time through upper digestive tracts was slightly but not significantly elongated compared with control subjects (14.4 +/- 8.3 vs 9.9 +/- 6.1 h). Significant elongation was observed in transit time through the lower digestive tracts or the whole gut (44.6 +/- 20.9 and 57.9 +/- 22.3 h, respectively) compared with control subjects (23.3 +/- 8.5 and 33.2 +/- 11.0 h). The transit time of the markers from stomach to small intestine was highly correlated (r = 0.693) with plasma concentration of acetaminophen. The transit time through either the whole colon (r = 0.564) or the whole gut (r = 0.630) was highly correlated with CV(R-R).
CONCLUSIONS: These findings suggest that the radiopaque marker method is a useful tool for detecting the sections of the digestive tract responsible for gut motility disturbances. In type II diabetics with no neuropathic symptoms, the lower digestive tracts may deteriorate prior to the impairment of upper digestive tracts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824881     DOI: 10.1046/j.1440-1746.2000.02076.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  14 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Authors:  Jia Li; Hai-Fang Guo; Can Liu; Zeyu Zhong; Li Liu; Xiao-Dong Liu
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

Review 3.  Upper gastrointestinal sensory-motor dysfunction in diabetes mellitus.

Authors:  Jingbo Zhao; Jens Brøndum Frøkjaer; Asbjørn Mohr Drewes; Niels Ejskjaer
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

4.  Clinical pharmacology of daikenchuto assessed by transit analysis using radiopaque markers in patients with colon cancer undergoing open surgery: a multicenter double-blind randomized placebo-controlled study (JFMC39-0902 additional study).

Authors:  Hidetoshi Katsuno; Koutarou Maeda; Masatoshi Ohya; Kazuhiko Yoshioka; Akira Tsunoda; Keiji Koda; Hiroyoshi Matsuoka; Hiroki Ohge; Satoshi Morita; Shigetoyo Saji; Takashi Kanematsu; Masaki Kitajima
Journal:  J Gastroenterol       Date:  2015-07-11       Impact factor: 7.527

5.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Ranko Skrbic; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Arch Drug Inf       Date:  2008-07

6.  The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology.

Authors:  I Sarosiek; K H Selover; L A Katz; J R Semler; G E Wilding; J M Lackner; M D Sitrin; B Kuo; W D Chey; W L Hasler; K L Koch; H P Parkman; J Sarosiek; R W McCallum
Journal:  Aliment Pharmacol Ther       Date:  2009-10-08       Impact factor: 8.171

7.  Changes of phasic and tonic smooth muscle function of jejunum in type 2 diabetic Goto-Kakizaki rats.

Authors:  Jing-Bo Zhao; Peng-Min Chen; Hans Gregersen
Journal:  World J Diabetes       Date:  2013-12-15

8.  The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.

Authors:  Momir Mikov; Hani Al-Salami; Svetlana Golocorbin-Kon; Ranko Skrbic; Aleksandar Raskovic; J Paul Fawcett
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

9.  Enhanced Intestinal Motility during Oral Glucose Tolerance Test after Laparoscopic Sleeve Gastrectomy: Preliminary Results Using Cine Magnetic Resonance Imaging.

Authors:  Vo Nguyen Trung; Hiroshi Yamamoto; Akira Furukawa; Tsuyoshi Yamaguchi; Satoshi Murata; Masahiro Yoshimura; Yoko Murakami; Shigetaka Sato; Hideji Otani; Satoshi Ugi; Katsutaro Morino; Hiroshi Maegawa; Tohru Tani
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus.

Authors:  Akio Kuroda; Hideaki Kaneto; Satoshi Kawashima; Kenya Sakamoto; Mitsuyoshi Takahara; Toshihiko Shiraiwa; Tetsuyuki Yasuda; Naoto Katakami; Taka-Aki Matsuoka; Iichiro Shimomura; Munehide Matsuhisa
Journal:  J Diabetes Investig       Date:  2012-08-21       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.